EpicentRx
EpicentRx is an innovation-driven clinical-stage drug and device company that puts the emphasis on “ease” – ease of treatment, ease of side effects and ease of symptoms during the treatment of a range of diseases including lung cancer, head and neck cancer and different inflammatory disorders for which the company has received several grants and orphan designations.
Latest EpicentRx Content
Product News
EpicentRx Receives Fast Track Designation From the U.S. FDA for Lead Asset
EpicentRx, Inc. has announced that the FDA has granted Fast Track Designation to RRx-001 for the prevention/attenuation of severe oral mucositis in chemotherapy and radiation-treated head & neck cancer patients.
Industry Insight
The Case for RRx-001 as a Radiation Countermeasure
This article overviews the science behind the potential use of RRx-001as a “radiation buster” with anti-inflammatory and anti-free radical properties to prevent or reduce both GI-ARS and H-ARS.
Advertisement
